Q-Line Biotech
Q-Line Biotech (QLINE) share price was ₹544.45 at the 28 Oct 2026 close; market capitalisation ₹1,270 Cr; P/E (TTM) 25.80; sector Healthcare. In the Mar 2026 quarter, revenue fell 8.8% year on year to ₹198 Cr and net profit was ₹34 Cr, against ₹9 Cr a year earlier (compared with Mar 2025). Promoters held 67.51% of Q-Line Biotech in Sep 2026, down 29.26 percentage points from Sep 2025.
Key Fundamentals
SMEMedical EquipmentHealthcarePrice-based figures as of 28 Oct 2026, 15:54 IST · TTM
Peer Comparison
Healthcare › Medical Equipment › Medical Equipment & Supplies
| ₹1,476.00 | 47.48 | 14,961 Cr | 4.82 | 0.24% | 10.18% | 13.33% | 2,115 Cr | 313 Cr | |
| ₹26.66 | 70.16 | 1,745 Cr | 3.81 | 0.20% | 8.11% | 12.69% | 373 Cr | 24 Cr | |
| ₹304.60 | 145.74 | 1,621 Cr | 2.55 | 0.66% | 2.26% | 4.82% | 468 Cr | 11 Cr | |
| Q-Line Biotech (this company) | ₹544.45 | 25.80 | 1,270 Cr | 2.60 | 0.00% | 22.63% | 26.37% | 201 Cr | 34 Cr |
| ₹181.39 | 32.33 | 998 Cr | 4.10 | 0.00% | 10.83% | 11.51% | 289 Cr | 31 Cr | |
| ₹572.55 | — | 832 Cr | 5.31 | 0.00% | 13.22% | 19.52% | — | — | |
| Median 6 companies | ₹424.53 | 47.48 | 1,445 Cr | 3.96 | 0.10% | 10.51% | 13.01% | 373 Cr | 31 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Weaknesses
1- Debtor days have increased from 92.7 to 134 days.
Technical Indicators
Oscillators
Bullish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 31% · Mar 2026
Quarterly Results
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21% | 31% |
| Other Income | -11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| PBT | 22 | 46 |
| Tax % | 71% | 26% |
| Net Profit | 9 | 34 |
| EPS (₹) | 56.13 | 21.14 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 183 | 203 | 313 | 342 |
| Expenses | 149 | 165 | 242 | 244 |
| Operating Profit | 34 | 38 | 71 | 98 |
| OPM % | 18% | 19% | 23% | 29% |
| Other Income | 2 | 3 | -14 | 5 |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| PBT | 30 | 31 | 35 | 73 |
| Tax % | 28% | 29% | 55% | 23% |
| Net Profit | 32 | 34 | 19 | 56 |
| EPS (₹) | 204 | 219 | 122 | 34.24 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74 | 97 | 166 | 225 |
| Other Liabilities | 51 | 81 | 99 | 87 |
| Total Liabilities | 252 | 339 | 455 | 559 |
| Fixed Assets | 23 | 60 | 91 | 158 |
| CWIP | 12 | 19 | 63 | 19 |
| Investments | 16 | 29 | 0 | 0 |
| Other Assets | 201 | 232 | 302 | 381 |
| Total Assets | 252 | 339 | 455 | 559 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 25 | -24 | 17 | 16 |
| Investing | -26 | -45 | -77 | -29 |
| Financing | 26 | 17 | 53 | 42 |
| Net Cash Flow | 25 | -52 | -7 | 29 |
| Free Cash Flow | -5 | -72 | -53 | -19 |
| CFO/OP | 111 | -39 | 36 | 43 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 225 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | -44 | 51 | 45 | 62 |
| ROCE % | — | 16% | 24% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Q-Line Biotech insights
55 extracted metrics + investor summaries across FY23–FY26.
Documents
Frequently Asked Questions about Q-Line Biotech
What does Q-Line Biotech Ltd do?
Where is Q-Line Biotech Ltd (QLINE) listed?
Which sector does Q-Line Biotech Ltd belong to?
What is the market capitalisation of Q-Line Biotech Ltd?
What is the PE ratio of Q-Line Biotech Ltd?
What is the 52-week high and low of Q-Line Biotech Ltd?
What is the Return on Equity (ROE) of Q-Line Biotech Ltd?
Company Information
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/QLINE.md for Q-Line Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.